By providing consent, you agree to receive direct marketing and promotional materials (for example email communications) relating to Entrepreneurs First's services or related products. In addition, EF may share your data with associated portfolio companies you have expressed an interest in.
If you experience any technical issues, please get in touch with [email protected].
Read and confirm
By accessing this website here (“website”), you signify your unconditional agreement with and understanding of the terms of use and legal information pertaining to both this website and any information provided on this website hereon (“Site Content”). Full terms can be found here.
This communication is only intended for professional or accredited investors who have the relevant experience, knowledge and competence to make their own investment decisions and properly assess the risks involved. Entrepreneurs First Investment Manager LLP (“EFIM”) does not act as an ‘independent financial adviser’ for the purposes of UK law and cannot be held responsible for any financial or other consequences resulting from the decision you may make on the basis of this Site Content.
The information provided on this website and Site Content is not intended as a recommendation to purchase, sell or hold any shares or security or suggest that you pursue any investment style or strategy. Under no circumstances should anything herein be construed as an offer to sell or solicitation of interest to purchase any securities, including any securities of EFIM or any entities managed or advised by EFIM (together being, “Entrepreneurs First”) or any securities of Entrepreneurs First’s portfolio companies.
Before investing in any product, an investor should conduct their own risk analysis, fully understand all the risks involved and consult with their own professional advisors before making an investment decision, if there is any doubt as to the suitability of the products or services offered. Investing involves risk of loss, including risk of losing substantially all of your investment, which you should be prepared to bear.
Please click to confirm you have read and understood the information above. By doing so, you confirm that you are qualified as an investor to access the website and Site Content as described above.
Added to Shortlist
Request intro
My shortlist
No companies shortlisted
Fill in your details to request an introduction to your shortlisted companies.
SUMMER '24
BATCH
Compile a shortlist of companies and request multiple introductions at once.
AMT
AI employee for partnering with 100x more influencers. AMT signed contracts worth over $450K in annualized revenue in its first 3 months, and is now managing thousands of influencers through its platform, aiming to achieve full automation with no human in the loop.
Delaware C
Axiom Therapeutics
Discovering covalent drugs using ML-accelerated physics simulations to treat undruggable cancers. Axiom’s foundational model predicts covalent drug interactions with cancer-causing proteins. They are currently piloting with biotechs and academic labs, and are advised by 4 world-leading scientists and commercial experts.
Delaware C
Axiom Therapeutics
Discovering covalent drugs using ML-accelerated physics simulations to treat undruggable cancers. Axiom’s foundational model predicts covalent drug interactions with cancer-causing proteins. They are currently piloting with biotechs and academic labs, and are advised by 4 world-leading scientists and commercial experts.
Briefcase
The world's first AI-native accounting automation platform. Briefcase won one of the UK's top 100 accounting firms as their first customer. They have now expanded to 5 firms across the UK and are doubling the total number of transactions processed through their platform every month.
United Kingdom
Fabric
Plaid for search and social data: user context as an API. In under 3 months, Fabric is being integrated into the apps and websites of large e-commerce retailers and AI startups that service millions of users. Fabric's forward bookings are worth $300K annually, and their late-stage sales pipeline is worth $1M+.
Delaware C
Fabric
Plaid for search and social data: user context as an API. In under 3 months, Fabric is being integrated into the apps and websites of large e-commerce retailers and AI startups that service millions of users. Fabric's forward bookings are worth $300K annually, and their late-stage sales pipeline is worth $1M+.
Genie Fertility
Novel diagnostic tests that access womb tissue non-invasively, halving the cost of IVF by improving fertility. Genie has already run a clinical validation study and is working with world leading advisors from Harvard and the University of Cambridge, UK. They have also secured research collaboration offers from multiple institutions, as well as commercial lab partnerships.
Delaware C
Genie Fertility
Novel diagnostic tests that access womb tissue non-invasively, halving the cost of IVF by improving fertility. Genie has already run a clinical validation study and is working with world leading advisors from Harvard and the University of Cambridge, UK. They have also secured research collaboration offers from multiple institutions, as well as commercial lab partnerships.
Iris Lab
Powering mobile robotic systems with continuous laser energy to unlock their full potential. Iris Lab has already signed 6 POCs and 10+ additional LOIs with leading drone manufacturers across Europe and the US. They have also secured a €110K research grant with the leading photovoltaic lab in Europe.
Delaware C
Iris Lab
Powering mobile robotic systems with continuous laser energy to unlock their full potential. Iris Lab has already signed 6 POCs and 10+ additional LOIs with leading drone manufacturers across Europe and the US. They have also secured a €110K research grant with the leading photovoltaic lab in Europe.
Kiyo
AI personal stylist that learns what you love and finds your next perfect wardrobe pieces. 90% of users say Kiyo's understanding of their style choices is accurate and helps them find clothes they love in 3 out of 5 searches.
Delaware C
Korda
The all-in-one platform for the next generation of music creators. Korda has already acquired paying customers with a 84% retention rate. They have also secured key partnerships to distribute music to 100+ streaming platforms.
United Kingdom
Level Zero Health
Pioneering continuous hormone monitoring. Level Zero has a pipeline of $1.5M in LOIs and pilot studies with some of the world-leading fertility clinics. They have already proven the effectiveness of their sensor in various concentrations for all analytes.
Delaware C
Luo
The first pan-African neobank for importers. Luo has already onboarded 40 customers. They reached $1M weekly transactions in their first 6 weeks, translating to $2M annualized revenue.
Delaware C
Nook Biosciences
Pioneering microbiomics to ensure every drug works the first time. Nook Bio has established exclusive partnerships with top hospitals and institutes in the Bay Area and globally to generate proprietary data and develop innovative high-throughput methods. Their pipeline is already live and actively generating data, and they are in advanced discussions with 3 major pharmaceutical companies.
Delaware C
Nook Biosciences
Pioneering microbiomics to ensure every drug works the first time. Nook Bio has established exclusive partnerships with top hospitals and institutes in the Bay Area and globally to generate proprietary data and develop innovative high-throughput methods. Their pipeline is already live and actively generating data, and they are in advanced discussions with 3 major pharmaceutical companies.
Nplicon
Next-generation PCR machines that are 10x faster and 70% cheaper. Nplicon's PCR machine prototype is already lab-tested and outperforming state-of-the-art commercial machines. The company is in a co-development partnership with the no.1 PCR-based infectious disease laboratory in the US and has onboarded the ex-Head of PCR R&D at Thermo Fisher as an advisor.
Delaware C
Nplicon
Next-generation PCR machines that are 10x faster and 70% cheaper. Nplicon's PCR machine prototype is already lab-tested and outperforming state-of-the-art commercial machines. The company is in a co-development partnership with the no.1 PCR-based infectious disease laboratory in the US and has onboarded the ex-Head of PCR R&D at Thermo Fisher as an advisor.
Pitri
Unlocking the potential of natural fungi to create high-performing non-toxic colorants. Pitri already has patents filed and has developed 3 POCs in beauty products, packaging, and paints. They have onboarded an ex-Stanford technical lead, and secured over $20K in grant funding for fermentation scale-up and safety testing.
Delaware C
Pitri
Unlocking the potential of natural fungi to create high-performing non-toxic colorants. Pitri already has patents filed and has developed 3 POCs in beauty products, packaging, and paints. They have onboarded an ex-Stanford technical lead, and secured over $20K in grant funding for fermentation scale-up and safety testing.
Radical
Foundational models for personalized cancer treatment trained on billions of patient data points. Radical is the only company in history to have gained access to the highest quality multi-modal dataset in the US with over 6.5M patients from the top hospital in San Francisco. They are on track for clinical validation and deployment with partners in the Bay Area by Q1 2025.
Delaware C
Radical
Foundational models for personalized cancer treatment trained on billions of patient data points. Radical is the only company in history to have gained access to the highest quality multi-modal dataset in the US with over 6.5M patients from the top hospital in San Francisco. They are on track for clinical validation and deployment with partners in the Bay Area by Q1 2025.
Thalya
RNAi spray to boost nitrogen uptake in crops, unlocking $250B in annual value for farmers and slashing 4% of global greenhouse gas emissions. Thalya has signed 4 POC contracts covering 320 acres of land in key US corn-producing states. This sets the path to large-scale commercialization by 2027, unlocking an $18M ACV potential through farmers' networks.
Delaware C
Thalya
RNAi spray to boost nitrogen uptake in crops, unlocking $250B in annual value for farmers and slashing 4% of global greenhouse gas emissions. Thalya has signed 4 POC contracts covering 320 acres of land in key US corn-producing states. This sets the path to large-scale commercialization by 2027, unlocking an $18M ACV potential through farmers' networks.
Toolkit
Easy-to-customize ERP for Excel-based SMBs. Toolkit is the first ERP system to convert existing ops Excel spreadsheets into tailored ERPs without consultants. Toolkit is closing a $30K ARR contract with a rust-belt manufacturer, with a further $120K ARR worth of contracts in the pipeline.
Delaware C
VIBE
A playful AI for daily reflection with your friends. VIBE launched a beta showcasing AI’s ability to deepen human connection. 30-day retention for users in a VIBE group is 84%. Many have ditched their old group chats to make VIBE chats the default place to talk with their friends.
Delaware C